These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1848053)

  • 1. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.
    Plotkin SA; Starr SE; Friedman HM; Brayman K; Harris S; Jackson S; Tustin NB; Grossman R; Dafoe D; Barker C
    Ann Intern Med; 1991 Apr; 114(7):525-31. PubMed ID: 1848053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial.
    Brayman KL; Dafoe DC; Smythe WR; Barker CF; Perloff LJ; Naji A; Fox IJ; Grossman RA; Jorkasky DK; Starr SE
    Arch Surg; 1988 Dec; 123(12):1502-8. PubMed ID: 2847687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.
    Plotkin SA; Higgins R; Kurtz JB; Morris PJ; Campbell DA; Shope TC; Spector SA; Dankner WM
    Transplantation; 1994 Dec; 58(11):1176-8. PubMed ID: 7992358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Lancet; 1984 Mar; 1(8376):528-30. PubMed ID: 6142252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates.
    Sachs GW; Simmons RL; Balfour HH
    Vaccine; 1984 Sep; 2(3):215-8. PubMed ID: 6099649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for the prevention of human cytomegalovirus infection.
    Plotkin SA; Starr SE; Friedman HM; Gonczol E; Brayman K
    Rev Infect Dis; 1990; 12 Suppl 7():S827-38. PubMed ID: 2173112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
    Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
    Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
    Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
    J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial.
    Glazer JP; Friedman HM; Grossman RA; Starr SE; Barker CF; Perloff LJ; Huang ES; Plotkin SA
    Ann Intern Med; 1979 Nov; 91(5):676-83. PubMed ID: 227299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial.
    Griffiths PD; Stanton A; McCarrell E; Smith C; Osman M; Harber M; Davenport A; Jones G; Wheeler DC; O'Beirne J; Thorburn D; Patch D; Atkinson CE; Pichon S; Sweny P; Lanzman M; Woodford E; Rothwell E; Old N; Kinyanjui R; Haque T; Atabani S; Luck S; Prideaux S; Milne RS; Emery VC; Burroughs AK
    Lancet; 2011 Apr; 377(9773):1256-63. PubMed ID: 21481708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
    Vincenti F; Budde K; Merville P; Shihab F; Ram Peddi V; Shah M; Wyburn K; Cassuto-Viguier E; Weidemann A; Lee M; Flegel T; Erdman J; Wang X; Lademacher C
    Am J Transplant; 2018 Dec; 18(12):2945-2954. PubMed ID: 29745007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.
    Balfour HH; Chace BA; Stapleton JT; Simmons RL; Fryd DS
    N Engl J Med; 1989 May; 320(21):1381-7. PubMed ID: 2541335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.
    Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM
    J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial.
    Snydman DR; Werner BG; Dougherty NN; Griffith J; Rubin RH; Dienstag JL; Rohrer RH; Freeman R; Jenkins R; Lewis WD; Hammer S; O'Rourke E; Grady GF; Fawaz K; Kaplan MM; Hoffman MA; Katz AT; Doran M;
    Ann Intern Med; 1993 Nov; 119(10):984-91. PubMed ID: 8214995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
    Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE
    J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.